SELLAS Life Sciences Group, Inc. (SLS)
Develops cancer immunotherapy drugs targeting tumor proteins to boost the immune system's ability to fight cancer.
$10.09-0.07%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+507.8%
The outlook
SLS is trading near the middle of its 52-week range with a mixed short-term trend. Analyst coverage leans notably bullish, with the average price target sitting roughly 173% above the current price. The overall sentiment skews toward optimism, though recent price momentum remains choppy.
What’s behind the score
Price trendMixed vs its moving averages
52-week range60% of the way from its 52-week low to high
Price targetAvg target +173% vs current price
Analyst price target
~12-month · 2 analysts$27.50average target+172.5% vs now
Now $10.09
Low $25.00High $30.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.98B
52-wk high
$15.88
52-wk low
$1.39
50-day avg
$10.25
200-day avg
$5.24
Trailing P/E
—